Lyra Therapeutics, Inc. · OTC:LYRA
Lyra Therapeutics — Combined Otolaryngology Spring Meetings (COSM) 2021
15 slides from Lyra Therapeutics's conference presentation, Apr 13, 2021
Slide 1: Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: LANTERN Phase 2 results
Anders Cervin1, Joanne Rimmer2, Agnieszka Wrobel3, Yogen Abelak4, Lindsay Brayton5, Yina Kuang5 1University of Queensland Centre for Clinical Research, Royal Brisbane & Women’s Hospital Campus, Herston, QLD, Australia; 2Monash Health and Department of Surgery, Monash University, Melbourne, Australia
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including state
Slide 3: Topical steroids used to treat CRS are suboptimal
Topical steroids used to treat CRS are suboptimal1,2 Limited ability to reach inflammation deep within the sinonasal passages Rapid clearance rates Poor patient compliance 40-60% of CRS patients fail medical management and become candidates for functional endoscopic sinus surgery3 ~4 million CRS pat
Slide 4: LYR-210 for chronic rhinosinusitis
Being developed to provide sustained release of mometasone furoate deep in the middle meatus Adaptable mesh design conforms and adapts to patient’s anatomy Designed to be administered in an otolaryngologist’s office Designed to eliminate patient compliance issues LYR-210 is designed to provide 24 we
Slide 5: LANTERN Phase 2 study design
LANTERN PHASE 2 STUDY DESIGN Multicenter, randomized, blinded, controlled, dose-ranging trial Moderate-to-severe CRS Baseline SNOT-22: ~68 Approximately half had nasal polyps Primary Endpoint: Change in 4 cardinal symptoms composite score Secondary Endpoints include: SNOT-22 Symptom improvement over
Slide 6: LYR-210 well-tolerated throughout 24-week treatment period
Well-tolerated throughout the 24-week treatment period at both 2500µg and 7500µg doses No treatment-related SAEs Treatment-related AEs in Control and LYR-210 (7500µg) groups occurred at comparable rates Treatment-related AEs in more than 1 subject: Epistaxis: 3 subjects in LYR-210 (2500µg) group Rhi
Slide 7: 22-Item Sino-Nasal Outcome Test (SNOT-22)
22-ITEM SINO-NASAL OUTCOME TEST (SNOT-22) Mean change from baseline (CFBL) in SNOT-22 total score. Data represents LSM. P<0.05 is considered statistically significant to control. MCID = Minimal Clinically Important Difference. 1Hopkins et al., Clinical Otolaryngology 2009, 34, 447–454. LYR-210 achie
Slide 8: SNOT-22 responder analysis
SNOT-22 RESPONDER ANALYSIS % Subjects Achieved MCID in SNOT-221 1Data represents % of subjects that reported at least an 8.9-point decrease in the SNOT-22 total score as defined in Hopkins et al., Clinical Otolaryngology 2009, 34, 447–454. MCID = Minimal Clinically Important Difference. Left: Polyp
Slide 9: Composite of cardinal symptoms (4CS)
COMPOSITE OF 4 CARDINAL SYMPTOMS (4CS) Nasal Blockage, Facial Pain/Pressure, Nasal Discharge, and Loss of Smell Mean change from baseline (CFBL) in the 7-day average score in the 4CS composite score (nasal blockage, facial pain/pressure, nasal discharge (anterior/posterior), and loss of smell). 4CS
Slide 10: Dose-dependent improvement in the cardinal symptoms of CRS
LYR-210 achieved dose-dependent improvement in the cardinal symptoms of CRS Mean change from baseline (CFBL) in the 7-day average score in nasal blockage, facial pain/pressure, or nasal discharge (anterior/posterior) for all patients. Data represents LSM. P<0.05 is considered statistically significa
Slide 11: Cardinal symptoms of CRS: loss of smell and 3CS
Cardinal symptoms of crs Mean change from baseline (CFBL) in the 7-day average score in loss of smell for patients with moderate-to-severe baseline anosmia (≥ 2 baseline score in loss of smell): LYR-210 (7500µg) (n=15 patients), LYR-210 (2500µg) (n=20 patients), control (n=20 patients). Data represe
Slide 12: Ethmoid opacification
Ethmoid opacification Mean change from baseline (CFBL) in the bilateral ethmoid Zinreich score (composite score of anterior ethmoid and posterior ethmoid Zinreich scores) at 24 weeks. Data represents mean. P<0.05 is considered statistically significant to control. LYR-210 improved bilateral ethmoid
Slide 13: Time to first rescue treatment use
TIME TO First rescue treatment use Time to first rescue treatment use over 24 weeks. Event is rescue treatment used. Patients who did not achieve the event were censored at the end of treatment date or at the early termination date. LYR-210 (7500µg) (n=1 patient), LYR-210 (2500µg) (n=2 patients), sa
Slide 14: Conclusions
LYR-210 achieved a rapid and durable dose-dependent improvement in the cardinal symptoms of CRS and SNOT-22 throughout 24 weeks in subjects independent of polyp status from a single administration LYR-210 decreased ethmoid opacification and need for rescue treatment LYR-210 provided up to 24 weeks o
Slide 15: /V\/ ye Nf
x /V\/ ye Nf : MYYV\ LEAN \\
Lyra Therapeutics — Combined Otolaryngology Spring Meetings (COSM) 2021 on 6ix